CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, f ...

Core Viewpoint - Euroseas Ltd. reported strong financial results for the fourth quarter and full year of 2025, highlighting high profitability and robust charter rates, while also addressing challenges in the containership market [4][5][6]. Fourth Quarter 2025 Financial Highlights - Total net revenues reached $57.4 million, a 7.7% increase from $53.3 million in Q4 2024, driven by higher average time charter rates despite a decrease in the average number of vessels operated [9][12]. - Net income for the quarter was $40.5 million, compared to $24.4 million in Q4 2024, with earnings per share of $5.82 (basic) and $5.79 (diluted) [7][23]. - The average time charter equivalent rate for the quarter was $30,268 per day, up from $26,479 per day in the same period last year [12][41]. - Adjusted EBITDA for Q4 2025 was $40.7 million, an increase from $32.8 million in Q4 2024 [11][22]. Full Year 2025 Highlights - Total net revenues for 2025 were $227.9 million, a 7.0% increase from $212.9 million in 2024, attributed to a higher number of vessels and increased charter rates [25]. - Net income for the year was $137.0 million, up from $112.8 million in 2024, with earnings per share of $19.73 (basic) and $19.72 (diluted) [36]. - The average time charter equivalent rate for the year was $29,107 per day, compared to $28,054 per day in 2024 [25][41]. - Adjusted EBITDA for the full year was $155.9 million, compared to $135.8 million in 2024 [35]. Fleet and Charter Coverage - The company has a charter coverage of approximately 87% for 2026 and over 71% for 2027, with contracted revenues exceeding $550 million over the next five years [5][6]. - The fleet operated an average of 22.22 vessels in 2025, compared to 21.73 vessels in 2024 [25][41]. Market Conditions and Challenges - The containership market faces challenges such as high orderbook levels in large containership segments and potential reductions in demand due to resumed traffic through the Suez Canal [6]. - Euroseas operates in the feeder and intermediate size vessel segments, which are expected to see a contraction in supply, benefiting modern vessel owners [6]. Shareholder Returns - The company declared a quarterly dividend of $0.75 per share for Q4 2025, reflecting a 7% increase and providing an annualized yield of about 5% [8]. - As of February 25, 2026, the company repurchased 480,455 shares, representing about 6.8% of outstanding shares, under a $20 million share repurchase plan [7].

Core Insights - Intelligent Bio Solutions Inc. has successfully received and deployed its first shipment of Intelligent Fingerprinting Drug Screening Readers through a partnership with Syrma Johari, marking a significant step in scaling production capacity and validating the operational and financial benefits of the collaboration [1][3] - The partnership is expected to deliver annual production cost savings of over 40%, leading to an anticipated improvement of approximately 20 percentage points in gross margin annually [1][3] - The company has doubled its in-house production capacity for lateral flow test strips, enhancing vertical integration and accelerating research and development [1][4] Production and Manufacturing - The first shipment of readers is being deployed across key customer verticals such as construction, transportation, logistics, and manufacturing in the U.K. and Europe, supporting growing commercial demand [2] - The partnership with Syrma Johari has provided access to manufacturing capacity approximately four times greater than prior capabilities, allowing for accelerated fulfillment and cost savings [3] - The company has sourced advanced manufacturing equipment that has doubled its in-house production capacity for lateral flow test strips, improving margins and reducing lead times [4] Strategic Positioning - The successful deployment of the first shipment and increased production capacity positions the company to enter the U.S. market with operational strength and the ability to grow with demand [5] - The company is building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion and accelerates innovation [5] - Additional production shipments are expected throughout 2026 as the company continues to build inventory and expand its commercial footprint [5] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [6] - The system is designed to screen for recent drug use in workplace settings, providing results in under ten minutes, which is valuable for employers in safety-critical industries [6] - Current customer segments outside the U.S. include construction, manufacturing, transport, logistics, mining, drug treatment organizations, and coroners [6]

Core Insights - Shanghai experienced a significant increase in cultural and tourism consumption during the Spring Festival, with over 2,570 activities launched to attract visitors [1][2][4] Visitor Statistics - The city welcomed 21.6721 million visitors, marking an 8.36% year-on-year increase [3] - Total tourism consumption reached 25.614 billion yuan, a surge of 20.90% from the previous year [3] - The average hotel occupancy rate rose to 50.60%, up 3.10 percentage points year-on-year [3] Promotional Strategies - The promotion campaign utilized the outcomes of a high-level competition to enhance Shanghai's tourism appeal, integrating cultural, tourism, commerce, sports, and exhibition resources [4] - Over 130 in-depth Spring Festival tour routes were created, which became popular on online travel agencies through live-stream sales [5] Cultural Activities - Shanghai introduced premium IPs and launched 353 themed activities on the "Hu Xiaoyou" smart travel service platform, promoting science popularization and industrial tourism [6] - Key cultural landmarks hosted Spring Festival fairs and concerts, creating new urban rituals and attracting fans nationwide [7] Festive Atmosphere - The combination of traditional Chinese New Year vibes and modern cultural elements enhanced the festive atmosphere, with city-wide lantern shows illuminating the nights [8] - Intangible cultural heritage fairs and master chefs' kitchens were established, offering visitors authentic local culinary experiences [9] Future Outlook - Shanghai aims to further integrate cultural and tourism resources, pursue continuous product innovation, and enhance the overall experience of its cultural and tourism industry [10]

Core Insights - Silynxcom Ltd. has received a follow-on purchase order from an Asia-Pacific special forces unit for its advanced in-ear communication systems, indicating strong demand for its products in military applications [1][2]. Group 1: Product Features and Technology - The repeat order includes products with "talk-through-the-ear" technology, which enhances situational awareness and provides superior hearing protection in high-noise environments [2]. - The systems are designed for elite operators to maintain clear communication while protecting against both impulse and continuous noise, making them suitable for special operations [2]. Group 2: Company Reputation and Market Position - The CEO of Silynxcom expressed honor at the continued confidence shown by the special forces unit, viewing repeat business as a strong endorsement of the company's combat-proven solutions [3]. - The company emphasizes the reliability and operational value of its proprietary in-ear solutions, highlighting its growing traction in demanding international markets [3]. Group 3: Company Overview - Silynxcom Ltd. develops and sells ruggedized tactical communication headset devices that are field-tested and combat-proven, used in various high-stakes environments [4]. - The company's in-ear headsets integrate with professional-grade ruggedized radios, allowing users to communicate clearly while being protected from hazardous sounds [4]. - Silynxcom collaborates closely with military and law enforcement customers to enhance product functionality based on real-world feedback [4].

Core Insights - PolyPid Ltd. is an innovative biopharmaceutical company focused on enhancing treatment effectiveness at the point of care, with a diverse pipeline addressing unmet medical needs [4] Company Participation in Conferences - PolyPid management will participate in two investor conferences in March 2026, providing opportunities for one-on-one meetings with investors [2][3] Product Development - PolyPid's lead product, D-PLEX₁₀₀, has successfully met its primary and all key secondary endpoints in the Phase 3 SHIELD II trial aimed at preventing surgical site infections [4]

Core Viewpoint - 20/20 BioLabs has launched its OneTest for Longevity, a blood test that integrates inflammatory biomarkers, dietary habits, and scientific research to provide personalized health insights, utilizing IBM's watsonx.ai technology [1][2][3] Group 1: Product Launch and Features - The OneTest for Longevity solution calculates and displays an individual's risk of chronic diseases such as diabetes, dementia, and cardiovascular disease, offering personalized dietary recommendations based on biomarker levels [2] - The platform leverages IBM's advanced AI capabilities, including the Granite 4.0 foundation models and the Docling toolkit, to analyze nutritional research and deliver evidence-based health insights [3][6] - The test is available for purchase and is conducted in CLIA-licensed and CAP-accredited labs, although it has not sought FDA approval [3][7] Group 2: Partnerships and Technology - 20/20 BioLabs has partnered with DAISource to enhance its AI-enabled health solutions, aiming to improve public health through scalable and secure technology [3] - IBM's role is as an information technology provider, focusing on supporting enterprises with secure workloads in various sectors, including healthcare [4] Group 3: Company Background and Market Position - 20/20 BioLabs is an early market leader in laboratory-based blood tests for early detection and prevention of cancers and chronic diseases, with its stock listed on Nasdaq under the ticker symbol "AIDX" since February 19, 2026 [5][6] - The company also operates a Clinical Laboratory Innovation Accelerator (CLIAx) to assist overseas diagnostics startups in launching lab tests in the U.S. [8]

LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About ...

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida. The invitation-only event will c ...

New identity reflects Company’s evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. (“ ...